MCID: GRF003
MIFTS: 71

Graft-Versus-Host Disease

Categories: Genetic diseases, Blood diseases, Rare diseases

Aliases & Classifications for Graft-Versus-Host Disease

MalaCards integrated aliases for Graft-Versus-Host Disease:

Name: Graft-Versus-Host Disease 57 37 55 38
Graft Versus Host Disease 38 76 59 55
Graft-Versus-Host Disease, Protection Against 57 38 13
Graft-Versus-Host Disease, Susceptibility to 57 29 40
Graft-Vs-Host Disease 73
Gvhds 57
Gvh 59

Characteristics:

Orphanet epidemiological data:

59
graft versus host disease
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare immunological diseases


External Ids:

OMIM 57 614395
Orphanet 59 ORPHA39812
UMLS via Orphanet 74 C0018133
ICD10 via Orphanet 34 T86.0
KEGG 37 H00084
UMLS 73 C0018133

Summaries for Graft-Versus-Host Disease

OMIM : 57 Transplantation of hematopoietic stem cells is a successful therapy for some tumors derived from bone marrow precursors, such as certain leukemias and lymphomas, and it can be used to cure some primary immunodeficiencies and inherited hematopoietic stem-cell diseases. One of the major complications of allogeneic bone marrow transplantation is graft-versus-host disease (GVHD), in which mature donor T cells that contaminate the allogeneic bone marrow recognize the tissues of the recipient as foreign, causing a severe inflammatory disease characterized by rashes, diarrhea, and liver disease. GVHD is particularly virulent when there is a mismatch of a major major histocompatibility complex (MHC) class I or class II antigen. Most transplants are therefore undertaken only when the donor and recipient are HLA-matched sibs or, less frequently, when there is an HLA-matched unrelated donor. However, GVHD also occurs in the context of disparities between minor histocompatibility antigens, and immunosuppression must be used in every stem-cell transplant (summary by Janeway et al., 2005). At the core of the immunogenetic basis for GVHD is the diversity of HLA, killer immunoglobulin-like receptors (KIRs; see 604936), and cytokine genes. HLA class I molecules function as ligands for natural killer cell inhibitory KIRs, indicating that GVHD results from a complex interplay between innate and adaptive immune responses. Cytokines may modulate the intensity of tissue injury and inflammation in GVHD, and therefore cytokine polymorphisms in either patient or donor or both may explain individual risks of GVHD (review by Petersdorf and Malkki, 2006). (614395)

MalaCards based summary : Graft-Versus-Host Disease, also known as graft versus host disease, is related to chronic graft versus host disease and acute graft versus host disease. An important gene associated with Graft-Versus-Host Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Graft-versus-host disease and Innate Immune System. The drugs Azacitidine and Decitabine have been mentioned in the context of this disorder. Affiliated tissues include Bone, bone and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Graft-versus-host disease (GvHD) is a medical complication following the receipt of transplanted tissue... more...

Related Diseases for Graft-Versus-Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Graft-Versus-Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 514)
# Related Disease Score Top Affiliating Genes
1 chronic graft versus host disease 35.6 IFNG IL10 IL1A
2 acute graft versus host disease 33.6 ARHGAP45 FASLG GZMB IFNG IL10 IL2
3 bronchiolitis obliterans 33.0 GZMB IFNG IL10 IL6 TNF
4 bronchiolitis 31.5 IFNG IL10 IL6 TNF
5 keratoconjunctivitis 31.3 IFNG IL2 TNF
6 lichen planus 31.3 GZMB IFNG TNF
7 cytomegalovirus infection 31.2 IFNG IL10 IL6 TNF
8 cutaneous t cell lymphoma 30.9 GZMB IFNG IL2
9 hand, foot and mouth disease 30.9 IFNG IL10 IL6
10 exanthem 30.8 IL2 IL6 TNF
11 dermatitis, atopic 30.7 IFNG IL10 IL2 TNF
12 microscopic polyangiitis 30.5 HLA-B HLA-DRB1 IL10 TNF
13 post-transplant lymphoproliferative disease 30.5 IL10 IL1A IL6 TNF
14 anterior uveitis 30.5 HLA-A HLA-B IL6
15 t-cell large granular lymphocyte leukemia 30.5 FASLG GZMB IL2
16 erythema multiforme 30.5 FASLG GZMB IFNG IL2 TNF
17 pure red-cell aplasia 30.4 HLA-A HLA-B HLA-DRB1 IL2
18 lymphopenia 30.4 FAS FASLG IFNG IL2
19 uveitis 30.3 HLA-B IFNG IL10 IL1A TNF
20 pneumonia 30.3 IL10 IL1B IL6 TNF
21 herpes zoster 30.3 HLA-A IFNG IL10 IL2
22 lichen sclerosus 30.2 GZMB HLA-DQB1 HLA-DRB1 TNF
23 laryngitis 30.2 IL1B IL6 TNF
24 pericarditis 30.1 IL1B IL6 TNF
25 hemophagocytic lymphohistiocytosis 30.0 FAS GZMB IFNG IL10 TNF
26 monocytic leukemia 29.8 IFNG IL1B IL6 TNF
27 keratoconjunctivitis sicca 29.8 IL10 IL1A IL1B IL6 TNF
28 gingivitis 29.7 IL1A IL1B IL6 TNF
29 gastroenteritis 29.6 IFNG IL10 IL1B IL6 TNF
30 mouth disease 29.6 IFNG IL10 IL1B IL6 TNF
31 gastrointestinal system disease 29.6 IFNG IL10 IL1B IL6 TNF
32 panuveitis 29.5 HLA-B HLA-DQB1 HLA-DRB1 IL10 TNF
33 colitis 29.5 IFNG IL10 IL1B IL2 IL6 TNF
34 chronic granulomatous disease 29.5 IFNG IL1B TNF
35 hematopoietic stem cell transplantation 29.4 ARHGAP45 HLA-A HLA-B HLA-C IFNG IL10
36 paraneoplastic pemphigus 28.6 HLA-A HLA-B HLA-C HLA-DQB1 HLA-DRB1
37 aplastic anemia 28.2 FAS FASLG HLA-A HLA-B HLA-DRB1 IFNG
38 psoriasis 27.9 HLA-C IFNG IL10 IL1A IL1B IL2
39 multiple sclerosis 27.9 HLA-DQB1 HLA-DRB1 IFNG IL10 IL1B IL2
40 systemic lupus erythematosus 27.1 FASLG HLA-DPB1 HLA-DQB1 HLA-DRB1 IFNG IL10
41 autoimmune disease 26.9 FAS HLA-B HLA-DQB1 HLA-DRB1 IFNG IL10
42 hepatic veno-occlusive disease 11.7
43 punctate inner choroidopathy 11.0 IL10 TNF
44 tropical endomyocardial fibrosis 11.0 IL10 TNF
45 oral tuberculosis 11.0 IL2 TNF
46 scorpion envenomation 11.0 IL6 TNF
47 variola major 10.9 IFNG IL2
48 hyperlucent lung 10.9 IFNG IL10
49 leukomalacia 10.9 IL6 TNF
50 primary systemic mycosis 10.8 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Graft-Versus-Host Disease:



Diseases related to Graft-Versus-Host Disease

Symptoms & Phenotypes for Graft-Versus-Host Disease

Clinical features from OMIM:

614395

GenomeRNAi Phenotypes related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.47 HLA-A HLA-B HLA-C
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.47 HLA-A HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.47 HLA-A HLA-B HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.47 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.47 HLA-C
6 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.47 HLA-B HLA-C HLA-A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.47 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.47 HLA-A HLA-B HLA-C
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.47 HLA-A HLA-B HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.47 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.47 HLA-A HLA-B HLA-C
12 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.47 HLA-C
13 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.47 HLA-A HLA-B HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.47 HLA-A HLA-B HLA-C
15 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.47 HLA-C
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.89 IL1A IL1B IL2 TNF CD28 FAS
17 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.89 IL10 IL1A IL1B IL2 TNF CD28

MGI Mouse Phenotypes related to Graft-Versus-Host Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.22 CENPF FAS FASLG HLA-DQB1 IFNG IL10
2 hematopoietic system MP:0005397 10.14 CD28 FAS FASLG HLA-DQB1 IFNG IL10
3 digestive/alimentary MP:0005381 10.11 CD28 FAS FASLG HLA-DQB1 IFNG IL10
4 immune system MP:0005387 10.11 CD28 FAS FASLG HLA-DQB1 IFNG IL10
5 endocrine/exocrine gland MP:0005379 10.09 CD28 FAS FASLG HLA-DQB1 IFNG IL10
6 integument MP:0010771 9.97 CD28 FAS FASLG IFNG IL10 IL1A
7 liver/biliary system MP:0005370 9.86 FAS FASLG HLA-DQB1 IFNG IL10 IL2
8 neoplasm MP:0002006 9.85 CD28 FAS FASLG IFNG IL10 IL1A
9 respiratory system MP:0005388 9.56 FAS FASLG HLA-DQB1 IFNG IL10 IL2
10 vision/eye MP:0005391 9.23 CD28 FAS FASLG IFNG IL10 IL2

Drugs & Therapeutics for Graft-Versus-Host Disease

Drugs for Graft-Versus-Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 472)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azacitidine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 320-67-2 9444
2
Decitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 2353-33-5 451668
3
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
5
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
6
Lomustine Approved, Investigational Phase 4,Not Applicable 13010-47-4 3950
7
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
8
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
11
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
12
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
13
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 52-24-4 5453
14
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 159351-69-6 6442177
15
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 53123-88-9 5284616 6436030 46835353
16
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
17
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 152923-56-3, 179045-86-4
18
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
19
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
20
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1 170277-31-3
21
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
22
Iron Approved Phase 4 7439-89-6 23925
23
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3 171228-49-2 147912
24
Menthol Approved Phase 4,Phase 2,Phase 1,Not Applicable 2216-51-5 16666
25
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
26
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
28
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
29
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-14-6 5280793
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1406-16-2
31
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 67-97-0 6221 5280795
32 Semustine Experimental, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 13909-09-6
33
Treosulfan Investigational Phase 4,Phase 3,Phase 2,Phase 1 299-75-2 9296
34
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
35 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
36 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
37 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Cyclosporins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
39 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Folic Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1476)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
2 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
3 ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
4 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation Fro Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
5 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
6 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
7 Study Evaluating Sirolimus in Kidney Transplant Recipients in India Completed NCT00195481 Phase 4 Rapamune
8 Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus Completed NCT00195468 Phase 4 CYCLOSPORINE
9 A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients Completed NCT00195429 Phase 4 Tacrolimus;Sirolimus;prednisone
10 Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients Completed NCT00044720 Phase 4 Rapamune
11 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
12 Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload Completed NCT01335035 Phase 4 deferasirox
13 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Recruiting NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
14 Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Recruiting NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
15 Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis Recruiting NCT01856803 Phase 4 anti thymoglobulin
16 Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT Recruiting NCT02634294 Phase 4 Peg interferon alfa-2b
17 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
18 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Recruiting NCT02412423 Phase 4 post-transplantation cyclophosphamide
19 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Recruiting NCT03229200 Phase 4 Ibrutinib
20 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
21 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
22 A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Not yet recruiting NCT03190733 Phase 4 ATG
23 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Not yet recruiting NCT03176849 Phase 4
24 Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
25 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4 Itraconazole
26 The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye Terminated NCT00553735 Phase 4 Cyclosporine A 0.05%;Arificial Tear
27 Busulfan Pharmacokinetic Analysis and GST Polymorphism in Adults Undergoing Hematological Stem Cell Transplantation Withdrawn NCT01071486 Phase 4 Hematological Stem Cell Transplantation
28 Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
29 Extracorporeal Photopheresis for Acute Graft Versus Host Disease Unknown status NCT00179855 Phase 2, Phase 3
30 The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
31 Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
32 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
33 MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Unknown status NCT02270307 Phase 2, Phase 3 Cyclophosphamide
34 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Unknown status NCT01295710 Phase 3
35 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
36 Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia Unknown status NCT01145976 Phase 3 Cy-ATG;Flu-ATG
37 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
38 ALL-SCT BFM International- HSCT in Children and Adolescents With ALL Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
39 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
40 Randomized, Prospective, Multicenter Study to Compare Enteral Nutrition to Parenteral Nutrition as Feeding Support in Patients Presenting Malignant Hemopathy Who Underwent an Allogeneic Hematopoietic Stem Cell Transplantation. Unknown status NCT01955772 Phase 3 Enteral nutrition alanyl-glutamin, Dipeptiven
41 Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis Unknown status NCT01087398 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen);Cyclosporin, Methotrexate (GVHD prophylaxis)
42 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
43 P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies Unknown status NCT01854567 Phase 3
44 Allogeneic Transplantation For Severe Osteopetrosis Unknown status NCT00775931 Phase 2, Phase 3 Campath-1H;Cyclophosphamide;Busulfan;Fludarabine monophosphate
45 Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease Completed NCT01788501 Phase 2, Phase 3 Tacrolimus;Cyclosporine;Methotrexate
46 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease Completed NCT00726375 Phase 3 Etanercept (Enbrel)
47 Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease Completed NCT00031824 Phase 3 cyclosporine;hydroxychloroquine;prednisone;tacrolimus
48 Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease Completed NCT00043147 Phase 3 beclomethasone dipropionate;methylprednisolone;prednisone
49 Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3 ABX-CBL
50 Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease Completed NCT01699412 Phase 3 Clobetasol;Dexamethasone

Search NIH Clinical Center for Graft-Versus-Host Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Graft-Versus-Host Disease cell therapies at LifeMap Discovery.

Genetic Tests for Graft-Versus-Host Disease

Genetic tests related to Graft-Versus-Host Disease:

# Genetic test Affiliating Genes
1 Graft-Versus-Host Disease, Susceptibility to 29 IL10

Anatomical Context for Graft-Versus-Host Disease

MalaCards organs/tissues related to Graft-Versus-Host Disease:

41
Bone, T Cells, Bone Marrow, Myeloid, Liver, Kidney, Eye
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Graft-Versus-Host Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Graft-Versus-Host Disease

Articles related to Graft-Versus-Host Disease:

(show top 50) (show all 2186)
# Title Authors Year
1
The Role of MicroRNAs in Myeloid Cells during Graft-versus-Host Disease. ( 29410665 )
2018
2
HSCT-GAVE as a Manifestation of Chronic Graft versus Host Disease: A Case Report and Review of the Existing Literature. ( 29721346 )
2018
3
Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: characteristics and risk factors for infectious complications. ( 29380038 )
2018
4
Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria. ( 29330402 )
2018
5
Full-body physical therapy evaluation for pre- and post-hematopoietic cell transplant patients and the need for a modified rehabilitation musculoskeletal specific grading system for chronic graft-versus-host disease. ( 29348574 )
2018
6
Topical vitamin D analog for chronic graft versus host disease of the skin. ( 29335622 )
2018
7
Change of apheresis device decreased the incidence of severe acute graft-versus-host disease among patients after allogeneic stem cell transplantation with sibling donors. ( 29536557 )
2018
8
Novel management of vaginal chronic graft-versus-host disease causing haematometra and haematocolpos. ( 29705733 )
2018
9
Chronic graft versus host disease presenting as lichen planus pigmentosus. ( 29410549 )
2018
10
A prospective study of female genital chronic graft-versus-host disease symptoms, signs, diagnosis and treatment. ( 29752810 )
2018
11
TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells. ( 29960041 )
2018
12
The glucocorticoid receptor in recipient cells keeps cytokine secretion in acute graft-versus-host disease at bay. ( 29643984 )
2018
13
Graft-versus-host Disease-free, Relapse-free Survival After HLA-identical Sibling Peripheral Blood Stem Cell Transplantation With Tacrolimus-based Graft-versus-host Disease Prophylaxis in Japanese Patients. ( 29407317 )
2018
14
Longitudinal follow-up of response status and concomitant immunosuppression in patients treated with extracorporeal photopheresis for chronic graft versus host disease. ( 29740177 )
2018
15
TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and <i>In Silico</i> Search for Small Molecule Binders. ( 29967617 )
2018
16
Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. ( 29345306 )
2018
17
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft versus host disease: low incidence of lower gastrointestinal tract disease. ( 29351985 )
2018
18
Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease. ( 29363541 )
2018
19
TGF-I^-Induced CD8<sup>+</sup>CD103<sup>+</sup>Regulatory T Cells Show Potent Therapeutic Effect on Chronic Graft-versus-Host Disease Lupus by Suppressing B Cells. ( 29441062 )
2018
20
Photopheresis of a less than 10-kg child with acute graft versus host disease accompanied with hyperbilirubinemia: A case report. ( 29778715 )
2018
21
Renal Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: InvolvementA ofA Chronic Graft-Versus-Host Disease. ( 29854984 )
2018
22
Utility of tissue elafin as an immunohistochemical marker for diagnosis of acute skin graft-versus-host disease: a pilot study. ( 29882232 )
2018
23
The Therapeutic Effect of ICAM-1-Overexpressing Mesenchymal Stem Cells on Acute Graft-Versus-Host Disease. ( 29763906 )
2018
24
Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center. ( 29330403 )
2018
25
Total hysterectomy as hematocolpos treatment following bone marrow transplant. A rare complication of chronic graft-versus-host disease. ( 29329824 )
2018
26
Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. ( 29348127 )
2018
27
A phase II/III randomized, multicenter trial of Prednisone /Sirolimus vs Prednisone/Sirolimus/Calcineurin Inhibitor for treatment of chronic graft-versus-host disease: BMT CTN 0801. ( 29954931 )
2018
28
Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease. ( 29670626 )
2018
29
MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. ( 29720426 )
2018
30
Simple, Reproducible, and Efficient Clinical Grading System for Murine Models of Acute Graft-versus-Host Disease. ( 29403494 )
2018
31
Plasma vascular non-inflammatory molecule 3 is associated with gastrointestinal acute graft-versus-host disease in mice. ( 29311761 )
2018
32
Patient-reported outcomes and health status associated with chronic graft-versus-host disease. ( 29858386 )
2018
33
Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study. ( 29755674 )
2018
34
Vitiligo type cutaneous manifestation of chronic graft-versus-host disease. Case report. ( 29664513 )
2018
35
Two Cases and a Review of Graft-Versus-Host Disease and the Role of Hepatitis C Treatment in Liver Transplant Patients. ( 29954253 )
2018
36
Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: a single-center experience. ( 29707788 )
2018
37
Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter? ( 29446444 )
2018
38
18F-3'-deoxy-3'-fluorothymidine (FLT) PET imaging for the prediction of acute graft-versus-host disease in mouse hematopoietic stem cell transplant models. ( 29981461 )
2018
39
Correction: Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients. ( 29771974 )
2018
40
Progressive multifocal leukoencephalopathy after T-cell replete HLA-haploidentical transplantation with post-transplantation cyclophosphamide graft-versus-host disease prophylaxis. ( 29359846 )
2018
41
Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival. ( 29391524 )
2018
42
Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease. ( 29959747 )
2018
43
Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. ( 29758393 )
2018
44
Griscelli Syndrome with Fibronodular Sclerodermatous Chronic Graft Versus Host Disease. ( 29398817 )
2018
45
Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. ( 29684567 )
2018
46
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). ( 29379171 )
2018
47
Characterization of monocyte subtypes regarding their phenotype and development in the context of graft-versus-host disease. ( 29906586 )
2018
48
Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease. ( 28748621 )
2018
49
Circulating monocyte subsets in human chronic graft-versus-host disease. ( 29728699 )
2018
50
B-cell targeting in chronic Graft-versus-Host disease. ( 29437591 )
2018

Variations for Graft-Versus-Host Disease

Copy number variations for Graft-Versus-Host Disease from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 188553 4 66300000 70400000 Absence of gene UGT2B17 Graft versus host disease

Expression for Graft-Versus-Host Disease

Search GEO for disease gene expression data for Graft-Versus-Host Disease.

Pathways for Graft-Versus-Host Disease

Pathways related to Graft-Versus-Host Disease according to KEGG:

37
# Name Kegg Source Accession
1 Graft-versus-host disease hsa05332

Pathways related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 ARHGAP45 CD28 FASLG HLA-A HLA-B HLA-C
2
Show member pathways
13.78 CD28 FAS FASLG IFNG IL10 IL1A
3
Show member pathways
13.52 CD28 FAS FASLG IL10 IL1A IL1B
4
Show member pathways
13.42 CD28 FAS FASLG IL10 IL1A IL1B
5
Show member pathways
13.41 FASLG HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1
6
Show member pathways
13.14 FAS FASLG IFNG IL10 IL1B IL2
7
Show member pathways
13.12 FAS FASLG HLA-A HLA-B HLA-C IL2
8
Show member pathways
13 HLA-A HLA-B HLA-C HLA-DQB1 HLA-DRB1
9
Show member pathways
12.93 CD28 FAS FASLG GZMB HLA-A HLA-B
10 12.89 FAS FASLG IFNG IL2 IL6
11
Show member pathways
12.85 IFNG IL1A IL1B IL2 TNF
12 12.83 FAS FASLG IL1A IL1B TNF
13
Show member pathways
12.79 FAS FASLG IFNG IL1A IL1B TNF
14
Show member pathways
12.78 IL1A IL1B IL2 IL6 TNF
15
Show member pathways
12.74 FAS FASLG HLA-A HLA-B HLA-C IL6
16 12.73 CD28 FAS FASLG GZMB IFNG IL10
17
Show member pathways
12.73 HLA-A HLA-B HLA-C IFNG IL10 IL1A
18
Show member pathways
12.72 IFNG IL10 IL1B IL2 IL6 TNF
19
Show member pathways
12.72 CD28 FAS FASLG HLA-A HLA-B HLA-C
20
Show member pathways
12.7 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
21
Show member pathways
12.64 FAS FASLG GZMB HLA-A HLA-B HLA-C
22
Show member pathways
12.63 CD28 HLA-DPB1 HLA-DQB1 HLA-DRB1
23
Show member pathways
12.59 FASLG IL1A IL1B TNF
24
Show member pathways
12.56 CD28 FAS IFNG IL10 IL1A IL1B
25 12.54 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
26
Show member pathways
12.49 HLA-DPB1 HLA-DQB1 HLA-DRB1 IFNG IL10 IL1A
27 12.47 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
28
Show member pathways
12.46 IFNG IL1B IL2 IL6 TNF
29
Show member pathways
12.45 CD28 HLA-DQB1 HLA-DRB1 IL2
30
Show member pathways
12.45 CD28 IFNG IL10 IL1B IL2 IL6
31
Show member pathways
12.41 IFNG IL1A IL1B IL6 TNF
32
Show member pathways
12.41 HLA-DPB1 HLA-DQB1 HLA-DRB1 IFNG IL10 IL1A
33
Show member pathways
12.4 IFNG IL1B IL6 TNF
34
Show member pathways
12.38 FAS FASLG IFNG IL1A IL1B TNF
35
Show member pathways
12.36 FAS FASLG GZMB IL1A TNF
36
Show member pathways
12.36 FAS FASLG IFNG IL1B IL6 TNF
37
Show member pathways
12.35 IL10 IL1B IL2 IL6 TNF
38 12.33 FAS FASLG GZMB TNF
39
Show member pathways
12.33 CD28 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL2
40 12.32 IL10 IL1A IL1B IL6 TNF
41 12.32 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
42 12.31 HLA-A HLA-B HLA-C IL1A IL6
43 12.31 CD28 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1
44 12.31 HLA-DPB1 HLA-DQB1 HLA-DRB1 IFNG IL10 IL1A
45
Show member pathways
12.3 IL1A IL1B IL6 TNF
46
Show member pathways
12.29 CD28 HLA-DPB1 HLA-DQB1 HLA-DRB1
47
Show member pathways
12.21 IFNG IL10 IL1A IL1B IL2 IL6
48 12.2 IFNG IL1A IL1B IL2 IL6 TNF
49 12.19 IFNG IL1A IL1B TNF
50 12.18 CD28 IFNG IL10 IL2 IL6 TNF

GO Terms for Graft-Versus-Host Disease

Cellular components related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.91 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
2 external side of plasma membrane GO:0009897 9.85 CD28 FASLG HLA-DRB1 TNF
3 cell surface GO:0009986 9.81 CD28 FAS FASLG HLA-A HLA-B HLA-C
4 trans-Golgi network membrane GO:0032588 9.71 HLA-DPB1 HLA-DQB1 HLA-DRB1
5 recycling endosome membrane GO:0055038 9.69 HLA-A HLA-B HLA-C
6 phagocytic vesicle membrane GO:0030670 9.67 HLA-A HLA-B HLA-C
7 endocytic vesicle membrane GO:0030666 9.65 HLA-DPB1 HLA-DQB1 HLA-DRB1
8 transport vesicle membrane GO:0030658 9.63 HLA-DPB1 HLA-DQB1 HLA-DRB1
9 clathrin-coated endocytic vesicle membrane GO:0030669 9.54 HLA-DPB1 HLA-DQB1 HLA-DRB1
10 MHC class II protein complex GO:0042613 9.5 HLA-DPB1 HLA-DQB1 HLA-DRB1
11 MHC class I protein complex GO:0042612 9.43 HLA-A HLA-B HLA-C
12 ER to Golgi transport vesicle membrane GO:0012507 9.43 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
13 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.1 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
14 extracellular space GO:0005615 10.13 FASLG IFNG IL10 IL1A IL1B IL2
15 extracellular region GO:0005576 10.1 ARHGAP45 FAS FASLG IFNG IL10 IL1A

Biological processes related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 T cell receptor signaling pathway GO:0050852 9.99 CD28 HLA-DPB1 HLA-DQB1 HLA-DRB1
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.98 FASLG IL1A IL1B TNF
3 positive regulation of protein phosphorylation GO:0001934 9.96 FAS IFNG IL1B IL2 TNF
4 cytokine-mediated signaling pathway GO:0019221 9.95 FASLG IL10 IL1A IL1B IL2 IL6
5 positive regulation of DNA binding transcription factor activity GO:0051091 9.94 IL10 IL1B IL6 TNF
6 apoptotic signaling pathway GO:0097190 9.91 CD28 FAS FASLG TNF
7 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.9 FAS FASLG TNF
8 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.9 HLA-A HLA-B HLA-C
9 positive regulation of JNK cascade GO:0046330 9.9 IL1A IL1B TNF
10 regulation of insulin secretion GO:0050796 9.89 IFNG IL1B TNF
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 IFNG IL2 IL6
12 T cell costimulation GO:0031295 9.89 CD28 HLA-DPB1 HLA-DQB1 HLA-DRB1
13 type I interferon signaling pathway GO:0060337 9.88 HLA-A HLA-B HLA-C
14 response to glucocorticoid GO:0051384 9.88 IL10 IL6 TNF
15 regulation of signaling receptor activity GO:0010469 9.86 FASLG IFNG IL10 IL1A IL1B IL2
16 humoral immune response GO:0006959 9.85 CD28 IFNG IL6 TNF
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 IFNG IL1B TNF
18 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.83 IL1A IL1B TNF
19 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.82 IL1A IL1B IL2
20 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.81 HLA-A HLA-B HLA-C
21 positive regulation of interleukin-6 production GO:0032755 9.81 IL1A IL1B IL6 TNF
22 positive regulation of cytokine secretion GO:0050715 9.8 IL10 IL1A TNF
23 positive regulation of mitotic nuclear division GO:0045840 9.79 CD28 IL1A IL1B
24 extrinsic apoptotic signaling pathway GO:0097191 9.78 FAS FASLG IFNG TNF
25 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.76 IFNG IL1B TNF
26 positive regulation of interferon-gamma production GO:0032729 9.76 HLA-DPB1 IL1B IL2 TNF
27 regulation of regulatory T cell differentiation GO:0045589 9.75 CD28 IFNG IL2
28 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.74 HLA-DPB1 HLA-DQB1 HLA-DRB1
29 inflammatory response to antigenic stimulus GO:0002437 9.73 HLA-DRB1 IL1B
30 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.73 FAS FASLG
31 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.73 IL1A IL1B
32 positive regulation of immunoglobulin secretion GO:0051024 9.72 IL2 IL6
33 negative regulation of lipid storage GO:0010888 9.72 IL6 TNF
34 positive regulation of isotype switching to IgG isotypes GO:0048304 9.72 CD28 IL2
35 positive regulation of T cell proliferation GO:0042102 9.72 CD28 HLA-DPB1 IL1B IL2 IL6
36 positive regulation of chemokine biosynthetic process GO:0045080 9.71 IL1B TNF
37 endothelial cell apoptotic process GO:0072577 9.71 IL10 TNF
38 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.71 CD28 IL1A IL1B
39 ectopic germ cell programmed cell death GO:0035234 9.7 IL1A IL1B
40 regulation of establishment of endothelial barrier GO:1903140 9.7 IL1B TNF
41 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 IL10 IL1B TNF
42 negative regulation of cytokine secretion involved in immune response GO:0002740 9.69 IL10 TNF
43 positive regulation of fever generation GO:0031622 9.68 IL1B TNF
44 fever generation GO:0001660 9.68 IL1A IL1B
45 protection from natural killer cell mediated cytotoxicity GO:0042270 9.67 HLA-A HLA-B
46 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.67 HLA-DQB1 HLA-DRB1
47 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.67 HLA-A HLA-B HLA-C
48 sequestering of triglyceride GO:0030730 9.66 IL1B TNF
49 receptor biosynthetic process GO:0032800 9.65 IL10 TNF
50 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.65 HLA-DQB1 HLA-DRB1

Molecular functions related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 FASLG IFNG IL10 IL1A IL1B IL2
2 MHC class II receptor activity GO:0032395 9.26 HLA-DQB1 HLA-DRB1
3 peptide antigen binding GO:0042605 9.1 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
4 protein binding GO:0005515 10.11 ARHGAP45 CD28 CENPF FAS FASLG GZMB

Sources for Graft-Versus-Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....